Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: Implications for pregnant women

Life Sciences

Volumn 88, Issue 21-22, 2011, Pages 953-958

  McCance Katz, Elinore F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Cocaine; Drug interactions; HIV disease; Methadone; Pregnancy; Substance abuse

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BUPRENORPHINE; CARBAMAZEPINE; COCAINE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FLUCONAZOLE; GLYCOPROTEIN P; LOPINAVIR PLUS RITONAVIR; METHADONE; NALTREXONE; NEVIRAPINE; OPIATE; RIFABUTIN; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COGNITIVE DEFECT; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; OPIATE ADDICTION; PERIPHERAL NEUROPATHY; PREGNANCY; PREGNANT WOMAN; RESPIRATION DEPRESSION; REVIEW; RISK; SEDATION; SIDE EFFECT; SUBSTANCE ABUSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANTI-HIV AGENTS; BUPRENORPHINE; COCAINE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, INFECTIOUS; SUBSTANCE-RELATED DISORDERS;

EID: 79956193722     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.09.016     Document Type: Review

References (39)

1. P. Alcabes, and G.F. Friedland Injection drug use and human immunodeficiency virus infection Clin Infect Dis 20 1995 1467 1479
2. D. Back, S. Gibbons, and S. Khoo Pharmacokinetic drug interactions with nevirapine J Acquir Immune Defic Syndr 34 Suppl 1 2003 S8 S14
3. M.R. Brzezinski, B.J. Spink, and R.A. Dean Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs Drug Metab Dispos 25 1997 1089 1096 (Pubitemid 27396498)
4. M.N. Cobb, J. Desai, L.S. Brown Jr., P.N. Zannikos, and P.M. Rainey The effect of fluconazole on the clinical pharmacokinetics of methadone Clin Pharmacol Ther 63 6 1998 655 662 (Pubitemid 28327893)
5. Y. Chang, D.E. Moody, and E.F. McCance-Katz Novel metabolites of buprenorphine in human liver microsomes and human urine Drug Metab Dispos 34 2006 440 448 (Pubitemid 43290902)
6. Committee on Quality of Health Care in America: Institute of Medicine To err is human: building a safer health system 2000 National Academy Press Washington, D.C
7. G. Friedland, P. Rainey, P. Jatlow, L. Andrews, B. Damle, and E. McCance-Katz Pharmacokinetics of didanosine from encapsulated enteric coated bead formulation vs chewable tablet formulation in patients on chronic methadone therapy Paper Presented at: 14th International AIDS Conference July 2002 Barcelona, Spain
8. J.G. Gerber, S. Rosenkranz, and Y. Segal Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401 J Acquir Immune Defic Syndr 27 2001 153 160 (Pubitemid 32595166)
9. C. Iribarne, F. Berthou, and S. Baird Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes Chem Res Toxicol 9 1996 365 373 (Pubitemid 26079977)
10. H. Jones, R. Johnson, D. Jasinski, K. OGrady, and C. Chisolm Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome Drug Alcohol Depend 79 2005 1 10 (Pubitemid 41557119)
11. J. Kakko, M. Heilig, and S. Ihsan Buprenorphine and methadone treatment of opiate dependence drug in pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series Drug Alcohol Depend 96 2008 69 78
12. E.D. Kharasch, A. Walker, D. Whittington, C. Hoffer, and P.S. Bedynek Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity Drug Alcohol Depend 101 3 2009 158 168
13. M.J. Kreek, J.W. Garfield, C.L. Gutjahr, and L.M. Giusti Rifampin-induced methadone withdrawal N Engl J Med 294 20 1976 1104 1106
14. A.E. Langley, T.M. Lehman, J. Kirlangitis, and R. Zeid Cardiac and autonomic nervous system effects of l-alphacetylmethadol (LAAM) Arch Int Pharmacodyn Thér 259 1982 250 281
15. J. Lazarou, B. Pomeranz, and P.N. Corey Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies J Am Med Assoc 279 1998 1200 1205 (Pubitemid 28193431)
16. B.W. LeDuc, P.R. Sinclair, and L. Shuster Norcocaine and nhydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4 Pharmacology 46 1993 294 300 (Pubitemid 23099579)
17. P. Lopez, R. Velez, and V. Rivera Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infected persons Retrovirology 2 Suppl 1 2005 p142
18. L.A. Marsch The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis Addiction 93 4 1998 515 532 (Pubitemid 28188071)
19. E.F. McCance-Katz Office based treatment of opioid dependence with buprenorphine Harv Rev Psychiatry 12 2004 321 338
20. E.F. McCance-Katz, D.E. Moody, G. Morse, P. Pade, G. Friedland, and J. Baker Interactions between buprenorphine and antiretrovirals I: non-nucleoside reverse transcriptase inhibitors I: efavirenz and delavirdine Clin Infect Dis 43 Suppl 4 2006 S224 S234
21. E.F. McCance-Katz Drug interactions between opioids and infectious disease therapeutics: why should we care? American Society of Addiction Medicine Annual Meeting NIDA Symposium. New Orleans, LA April 2009
22. E.F. McCance-Katz, M.N. Gourevitch, J. Arnsten, J. Sarlo, P. Rainey, and P. Jatlow Modified directly observed therapy (MDOT) for injection drug users with HIV disease Am J Addict 11 2002 271 278 (Pubitemid 35332504)
23. E.F. McCance-Katz, P. Jatlow, P. Rainey, and G. Friedland Methadone effects on zidovudine (AZT) disposition (ACTG 262) J Acquir Immune Defic Syndr Hum Retrovirol 18 1998 435 443
24. E.F. McCance-Katz, D.E. Moody, G.D. Morse, Q. Ma, R. DiFrancesco, and G.H. Friedland Interaction between buprenorphine and atazanavir or atazanavir/ritonavir Drug Alcohol Depend 91 2007 269 278 (Pubitemid 47539730)
25. E.F. McCance-Katz, P. Rainey, G. Friedland, and P. Jatlow The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients Clin Infect Dis 37 2003 476 482 (Pubitemid 37011769)
26. E.F. McCance-Katz, P.M. Rainey, G. Friedland, T.R. Kosten, and P. Jatlow Effect of opioid dependence pharmacotherapies on zidovudine disposition Am J Addict 10 2001 296 307 (Pubitemid 34008323)
27. E.F. McCance-Katz, D.E. Moody, E. Morse, Q. Ma, and P. Rainey Lack of clinically significant drug interactions between nevirapine and buprenorphine Am J Addict 19 2010 30 37
28. E.F. McCance-Katz, P.M. Rainey, and P. Jatlow Effect of cocaine use on methadone pharmacokinetics in humans Am J Addict 19 2010 47 52
29. E.F. McCance-Katz, P.M. Rainey, and D.E. Moody Effect of cocaine use on buprenorphine pharmacokinetics in humans Am J Addict 19 2010 38 46
30. E.F. McCance-Katz, P. Rainey, P. Smith, G.D. Morse, G. Friedland, and B. Boyarsky Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine Am J Addict 15 2006 23 34 (Pubitemid 43207186)
31. E.F. McCance-Katz, L.S. Sullivan, and S. Nallani Drug interactions of clinical importance between the opioids, methadone and buprenorphine, and frequently prescribed medications: a review Am J Addict 19 2009 4 16
32. National Center for Health Statistics Health, United States With Chartbook Hyattsville, MD: 2009 Library of Congress Catalog Number 76-641496 2008
33. K. Neufeld, V. King, J. Peirce, K. Kolodner, R. Brooner, and M. Kidorf A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals Drug Alcohol Depend 97 1-2 2008 122 129
34. P. Pellinen, F. Stenbäck, and A. Kojo Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine Hepatology 23 3 1996 515 523 (Pubitemid 26087165)
35. E. Perucca Clinically relevant drug interactions with antiepileptic drugs Br J Clin Pharmacol 61 3 2006 246 255 (Pubitemid 43382623)
36. P.M. Rainey, G. Friedland, and E.F. McCance-Katz Interaction of methadone with didanosine (ddI) and stavudine (d4t) J Acquir Immune Defic Syndr Hum Retrovirol 24 2000 241 248
37. S. Schindler, H. Eder, R. Ortner, K. Rohrmeister, M. Langer, and G. Fischer Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy Addiction 98 2002 103 110 (Pubitemid 36044342)
38. S.A. Steedman, and Z.M. Younossi Hepatitis C: an update on a silent epidemic J Clin Gastroenterol 30 2000 125 143
39. Tip 2: Pregnant, substance-using women. CSAT/SAMHSA, DHHS Publication No. (SMA) 95-3056, 1993.